Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
| Autor: | Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-7 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1129-2369 1129-2377 |
| DOI: | 10.1186/s10194-021-01328-1 |
| Popis: | Abstract Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort. Methods This is a prospective study conducted in CM patients with and without medication overuse treated with monthly MAbs during 6 months (erenumab/galcanezumab). We collected headache characteristics, including acute medication intake, through an electronic diary. We compared patients (1) with and without MO at baseline, (2) with and without ongoing MO after treatment, defining MO resolution as |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink